New Jersey/New York ranks #3 on Genetic Engineering News’ “Top 10 U.S. Biopharma Clusters.“ GEN ranks New Jersey/NewYork region as third in the country and reports that New Jersey represents more than half of the region’s total lab space and accounts for 60% of the region’s industry jobs thanks to the State’s heritage pharma industry and a biotech segment specifically citing “industry giants Celgene and Amicus Therapeutics“.
Life sciences companies continue to choose New Jersey to call home, such as BAP Pharma, an award-winning UK specialist supplier of comparators for clinical trials, that opened its U.S. headquarters this past week in Landing, New Jersey — the company’s first facility located in the United States.
New Jersey’s life sciences community, known for its wealth of clinical and commercial development expertise, continues to deliver hope to Patients around the world. Companies, including BioNJ Members Allergan, Cancer Genetics, Celldex Therapeutics, Celator Pharmaceuticals, Helsinn and Novo Nordisk, report positive results on their clinical trials. See details below on these and others.
The New Jersey Economic Development Authority (EDA) just announced that applications for the State’s Technology Business Tax Certificate Transfer (NOL) Program are now available. The NOL program allows eligible technology and biotechnology companies to sell unused New Jersey net operating losses and research and development tax credits to unrelated profitable corporations — leading to cash-generating opportunities for product development.
Visit www.BioNJ.org to learn about the many upcoming events being hosted by BioNJ, including our HR Conference on May 12 and BioNJ’s Sixth Annual International BioPartnering Conference on May 26. Hope to see you there! Call if we can support you in any way!